Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laure Elens

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Pharmacogenomics|November 3, 2017
Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?Laure Elens, Vincent Haufroid
Therapeutic Advances in Psychopharmacology|September 2, 2022
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisationJuliette Lagreula, Philippe de Timary, Laure Elens, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 20, 2025
In vitro assessment of ATP-binding cassette transporters and their functional genetic polymorphisms on fluoroquinolone accumulation in human embryonic kidney 293 recombinant cell linesGwenaëlle Mahieu, Vincent Haufroid, Françoise Van Bambeke, et al.
Scientific Reports|July 13, 2016
Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinibGéraldine Dessilly, Nadtha Panin, Laure Elens, et al.
Iscience|March 24, 2025
A hollow fiber infection model to study intracellular and extracellular antibiotic activity against <i>Staphylococcus aureus</i>Gwenaëlle Mahieu, Laure Elens, Noémie Prebonnaud, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 19, 2018
Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?Gabriel Stillemans, Leila Belkhir, Dennis A Hesselink, et al.
Clinical Biochemistry|January 5, 2024
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapyEmilia Hoste, Vincent Haufroid, Louise Deldicque, et al.
European Journal of Clinical Pharmacology|November 11, 2020
Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic modelGabriel Stillemans, Leila Belkhir, Bernard Vandercam, et al.
Basic & Clinical Pharmacology & Toxicology|March 29, 2023
Prescribing and deprescribing trends in schizophrenia: An overview of inpatients in Belgium and in the Canadian province of QuébecJuliette Lagreula, Vincent Dagenais-Beaulé, Philippe de Timary, et al.
Clinical Pharmacokinetics|July 23, 2020
Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and SimulationsGabriel Stillemans, Leila Belkhir, Bernard Vandercam, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Pharmacogenomics|November 3, 2017
Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?Laure Elens, Vincent Haufroid
Therapeutic Advances in Psychopharmacology|September 2, 2022
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisationJuliette Lagreula, Philippe de Timary, Laure Elens, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 20, 2025
In vitro assessment of ATP-binding cassette transporters and their functional genetic polymorphisms on fluoroquinolone accumulation in human embryonic kidney 293 recombinant cell linesGwenaëlle Mahieu, Vincent Haufroid, Françoise Van Bambeke, et al.
Scientific Reports|July 13, 2016
Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinibGéraldine Dessilly, Nadtha Panin, Laure Elens, et al.
Iscience|March 24, 2025
A hollow fiber infection model to study intracellular and extracellular antibiotic activity against <i>Staphylococcus aureus</i>Gwenaëlle Mahieu, Laure Elens, Noémie Prebonnaud, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 19, 2018
Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?Gabriel Stillemans, Leila Belkhir, Dennis A Hesselink, et al.
Clinical Biochemistry|January 5, 2024
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapyEmilia Hoste, Vincent Haufroid, Louise Deldicque, et al.
European Journal of Clinical Pharmacology|November 11, 2020
Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic modelGabriel Stillemans, Leila Belkhir, Bernard Vandercam, et al.
Basic & Clinical Pharmacology & Toxicology|March 29, 2023
Prescribing and deprescribing trends in schizophrenia: An overview of inpatients in Belgium and in the Canadian province of QuébecJuliette Lagreula, Vincent Dagenais-Beaulé, Philippe de Timary, et al.
Clinical Pharmacokinetics|July 23, 2020
Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and SimulationsGabriel Stillemans, Leila Belkhir, Bernard Vandercam, et al.
Pageof 9